Frost & Sullivan Names Precision BioSciences’ Directed Nuclease Editor ‘Technology Innovation of the Year’
RESEARCH TRIANGLE PARK, North Carolina, May 12th, 2009 - Precision
- Precision BioSciences, Inc. today announced that its Directed Nuclease EditorTM (DNE) technology has been awarded the 2009 Genomics Technology Innovation of the Year by Frost & Sullivan, a leading market research and consulting firm. Precision’s breakthrough DNE technology platform was chosen due to its ability to target and modify regions of a cell’s genome with extremely high specificity. DNE’s rational design process, efficientmanufacturing capabilities, and breadth of applications were also cited as strengths.
“Precision is truly honored to have received this esteemed award,” said Matthew Kane, Precision’s CEO. “This independent validation of our technology by an objective, leading firm such as Frost & Sullivan is a terrific acknowledgement of the incredible efforts and achievements of Precision’s scientific co-founders and inventors of the DNE technology.”
“The DNE technology platform’s ability to direct site-specific genome modifications is enabling Precision to overcome a grand challenge in biotechnology,” notes Frost & Sullivan. “In our view, DNE’s ubiquitous nature and unmatched specificity places it as the current gold standard for genome engineering.”
“It has been a goal of ours to see the DNE technology utilized across nearly all facets of biotechnology," commented Derek Jantz, Precision’s Chairman and Vice President of Scientific Development. “This Technology Innovation Award is an incredibly gratifying recognition of Precision’s leading position in our field and will no doubt assist the Company in its commercialization efforts."
About Precision BioSciences Precision's mission is to utilize its engineered endonuclease technology to become the world leader in the field of genomic molecular biology. Precision’s proprietary Directed Nuclease Editor TM (DNE) technology enables the production of custom genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.
Precision's mission is to utilize its engineered endonuclease technology to become the world leader in the field of genomic molecular biology. Precision’s proprietary (DNE) technology enables the production of custom genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.
Precision's mission is to utilize its engineered endonuclease technology to become the world leader in the field of genomic molecular biology. Precision’s proprietary (DNE) technology enables the production of custom genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells. Precision BioSciences has already produced hundreds of custom endonucleases for partners and internal development that can precisely alter naturally occurring sequences within genomes. Precision has successfully partnered its DNE technology with several of the world’s largest agbiotech firms and is internally developing applications in biological production and human therapeutics. For additional information, please visit www.precisionbiosciences.com.